MPNRF | April 28, 2021
AOP Orphan and PharmEssentia announced its latest clinical results for Ropeginterferon alfa-2b in Polycythemia Vera
On June 25, 2017 at the 22nd Congress of European Hematology Association (EHA) conference held in Spain, AOP Orphan Pharmaceuticals AG of Austria and Taipei, Taiwan headquartered PharmEssentia announced the latest results from three of their clinical studies on Ropeginterferon alfa-2b for patients with Polycythemia Vera (PV). Click below for more details.
